Liba Weilin Pian (利巴韦林片)利巴韦林片
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 江西赣南制药有限公司Chinese legal name: 江西赣南制药有限公司
主要成分Active Ingredients
- 利巴韦林Liba Weilin
药物知识说明
利巴韦林是一种在国家药监局注册认定的药品。该药品含有利巴韦林-e1136c4c等成分。
该药品关联的活性成分包括：利巴韦林Liba Weilin。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：江西赣南制药有限公司Chinese legal name: 江西赣南制药有限公司。
您可以探索含有相同成分的其他药品：利巴韦林-e1136c4c成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 利巴韦林片) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 利巴韦林Liba Weilin.
Manufacturers recorded for this product: 江西赣南制药有限公司Chinese legal name: 江西赣南制药有限公司.
Explore other medicines containing the same ingredient: 利巴韦林 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 利巴韦林片Recorded Chinese name: 利巴韦林片
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 20mg20 mg
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 江西赣南制药有限公司Chinese legal name: 江西赣南制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20055615
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20055615
Manufacturer
Chinese legal name: 江西赣南制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20055615
生产企业
江西赣南制药有限公司(国产)
适应症
本品适用于呼吸道合胞病毒引起的病毒性肺炎与支气管炎，皮肤疱疹病毒感染。
用法用量
口服。 1.病毒性呼吸道感染:成人一次0.15g，一日3次，疗程7天。 2.皮肤疱疹病毒感染:成人一次0.3g，一日3次，疗程7天。 3.小儿每日按体重10mg/kg ，分4次服用，疗程7天，6岁以下小儿口服剂量未定。
不良反应
1.常见的不良反应有贫血、乏力等，停药后即消失。
2.较少见的不良反应有疲倦、头痛、失眠、食欲减退、恶心、呕吐、轻度腹泻、便秘等，并可致红细胞、白细胞及血红蛋白下降。
禁忌
对本品过敏者、孕妇禁用。
注意事项
1.有严重贫血、肝功能异常者慎用。
2.对诊断的干扰：口服本品后引起血胆红素增高者可高达25%。
3.尽早用药，呼吸道合胞病毒性肺炎病初3日内给药一般有效。
4.长期或大剂量服用对肝功能、血象有不良反应。
5.本品不宜用于未经实验室确诊为呼吸道合胞病毒感染的患者。
6.大剂量可引起血红蛋白含量下降。
贮藏
遮光，密封保存。
规格
20mg
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.